High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myelomaCAVO, M; BANDINI, G; MOTTA, M et al.Bone marrow transplantation (Basingstoke). 1998, Vol 22, Num 1, pp 27-32, issn 0268-3369Article

Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myelomaCAVO, M; TERRAGNA, C; TURA, S et al.Blood. 2000, Vol 96, Num 1, pp 355-357, issn 0006-4971Article

Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapyLEMOLI, R. M; MARTINELLI, G; TURA, S et al.Blood. 2000, Vol 95, Num 7, pp 2234-2239, issn 0006-4971Article

Selection and transplantation of autologous CD34⁺ B-lineage negative cells in advanced-phase multiple myeloma patients : a pilot studyLEMOLI, R. M; MARTINELLI, G; RONDELLI, D et al.British journal of haematology. 1999, Vol 107, Num 2, pp 419-428, issn 0007-1048Article

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failureTOSI, P; ZAMAGNI, E; RONCONI, S et al.Leukemia. 2000, Vol 14, Num 7, pp 1310-1313, issn 0887-6924Article

Clinical outcome of extramedullary plasmacytomaGALIENI, P; CAVO, M; PULSONI, A et al.Haematologica (Roma). 2000, Vol 85, Num 1, pp 47-51, issn 0390-6078Article

In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cellsTOSI, P; PELLACANI, A; VISANI, G et al.European journal of haematology. 1999, Vol 62, Num 3, pp 143-148, issn 0902-4441Article